Seems they've had some trouble in Canada with their swine flu vaccine provisions, leading to large line-ups and some disappointed people. It has beset Canada's health campaign against the H1N1 virus. Even though the huge pharmaceutical company Glaxo Smith Kline forewarned health authorities in Ottawa that switching to the production of this vaccine would slow down production little was done to compensate for this. Thus, Glaxo now have been ordered to manufacture a further 400,000 doses of the vaccine this week. The reason why the slowdown has occurred is that Glaxo switch from making a more adjuvenated version of the vaccine to a slimline vaccine catering especially batches for children and young women. However, production is expected to go into overdrive this week, and the health authorities in Ottawa are not expecting any more hiccups.
Cases such as in Ottawa, Canada, highlight how very rushed the whole process of releasing the h1n1 vaccine seems to have been compared to the trials of drug compounds that are rigorously tested before they can be released on the market. However, saying this we are constantly told this new vaccine is just a simple modification of the seasonal flu vaccine we've had for a few years now. Again time will tell just how successful the vaccine has been in preventing deaths from this flu.
1 comment:
That was an alarming news. viruses can easily penetrate to your body if you don't have combatants. vaccination is a must specially now that h1n1 has widely spread.
Post a Comment